Open Payments

California Pacific Medical Center

Type
Teaching hospital
Where
SAN FRANCISCO, CA
Medicare CCN
050047
Received
$1,180,921 in 74 records, 2025 ($10,682 general, $1,170,238 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment4$10,682
2025Research payment70$1,170,238

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC7$919,3322025
ABBVIE INC.24$125,9352025
PTC Therapeutics, Inc.3$38,3692025
Regeneron Pharmaceuticals, Inc.6$34,2872025
ARGENX US, INC.20$25,9542025
CSL Behring7$20,7332025
Incyte Corporation1$7,9992025
Medtronic, Inc.1$2,8882025
Organon Llc2$2,7362025
Chiesi USA, Inc.1$1,5002025
Cochlear Americas1$1,1532025
Medline Industries LP1$292025

By nature of payment

NatureRecordsAmount
Research payment70$1,170,238
Space rental or facility fees (teaching hospital only)2$9,499
Long term medical supply or device loan1$1,153
Debt forgiveness1$29

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Merck Sharp & Dohme LLC$501,334Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYSTUDY NAME#Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologo2025
2025-12-31Merck Sharp & Dohme LLC$135,921Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable 2025
2025-12-31Merck Sharp & Dohme LLC$37,894Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2025
2025-12-31Merck Sharp & Dohme LLC$22,662Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRP2025
2025-12-31Merck Sharp & Dohme LLC$350Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2025
2025-12-31Medline Industries LP$29Debt forgivenessCash or cash equivalent2025
2025-12-30ABBVIE INC.$18,658Research paymentCash or cash equivalentEPKINLY Drug, ONCOLOGYA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-12-22Merck Sharp & Dohme LLC$214,308Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin2025
2025-12-19Regeneron Pharmaceuticals, Inc.$5,524Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Res2025
2025-12-11ABBVIE INC.$7,450Research paymentCash or cash equivalentStudy Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa2025
2025-12-11Regeneron Pharmaceuticals, Inc.$1,741Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYExtended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3762025
2025-12-08ABBVIE INC.$3,750Research paymentCash or cash equivalentA Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl2025
2025-12-01ABBVIE INC.$7,000Research paymentCash or cash equivalentA Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl2025
2025-12-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-11-04ABBVIE INC.$4,657Research paymentCash or cash equivalentEPKINLY Drug, ONCOLOGYA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-11-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-10-29ARGENX US, INC.$2,100Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyOpen-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar2025
2025-10-29ARGENX US, INC.$1,000Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyOpen-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar2025
2025-10-29ARGENX US, INC.$750Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyOpen-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar2025
2025-10-29ARGENX US, INC.$550Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyOpen-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar2025
2025-10-29ARGENX US, INC.$550Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyOpen-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar2025
2025-10-29ARGENX US, INC.$150Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyOpen-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar2025
2025-10-23Regeneron Pharmaceuticals, Inc.$8,489Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Res2025
2025-10-13Merck Sharp & Dohme LLC$6,861Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 and Lenvatin2025
2025-10-03CSL Behring$64Research paymentCash or cash equivalentA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2025
2025-10-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-09-25ABBVIE INC.$15,639Research paymentCash or cash equivalentELAHERE Drug, ONCOLOGYMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Pla2025
2025-09-25ABBVIE INC.$600Research paymentCash or cash equivalentEPKINLY Drug, ONCOLOGYA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-09-24Organon Llc$2,500Research paymentCash or cash equivalent7339-0072025
2025-09-15Organon Llc$236Research paymentCash or cash equivalent7902-0032025
2025-09-04ABBVIE INC.$2,250Research paymentCash or cash equivalentStudy Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa2025
2025-09-03ABBVIE INC.$3,034Research paymentCash or cash equivalentEPKINLY Drug, ONCOLOGYA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-09-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-08-12ABBVIE INC.$134Research paymentCash or cash equivalentEPKINLY Drug, ONCOLOGYA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-08-11ABBVIE INC.$340Research paymentCash or cash equivalentA Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl2025
2025-08-11ABBVIE INC.$131Research paymentCash or cash equivalentA Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl2025
2025-08-05ABBVIE INC.$3,270Research paymentCash or cash equivalentEPKINLY Drug, ONCOLOGYA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-08-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-07-23ARGENX US, INC.$2,000Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyOpen-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar2025
2025-07-10ABBVIE INC.$4,932Research paymentCash or cash equivalentEPKINLY Drug, ONCOLOGYA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-07-07ABBVIE INC.$3,519Research paymentCash or cash equivalentA Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl2025
2025-07-02ABBVIE INC.$3,902Research paymentCash or cash equivalentEPKINLY Drug, ONCOLOGYA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-07-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-06-30PTC Therapeutics, Inc.$31,910Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2025
2025-06-18Chiesi USA, Inc.$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentKENGREAL Drug, CARDIOVASCULAR2025
2025-06-10Cochlear Americas$1,153Long term medical supply or device loanIn-kind items and servicesCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution2025
2025-06-04ABBVIE INC.$15,639Research paymentCash or cash equivalentELAHERE Drug, ONCOLOGYMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Pla2025
2025-06-03ABBVIE INC.$1,742Research paymentCash or cash equivalentEPKINLY Drug, ONCOLOGYA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-06-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-05-09ABBVIE INC.$3,410Research paymentCash or cash equivalentA Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl2025
2025-05-07ABBVIE INC.$3,522Research paymentCash or cash equivalentEPKINLY Drug, ONCOLOGYA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-05-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-04-30PTC Therapeutics, Inc.$994Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2025
2025-04-28CSL Behring$4,186Research paymentCash or cash equivalentA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2025
2025-04-09ABBVIE INC.$8,051Research paymentCash or cash equivalentA Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl2025
2025-04-03ABBVIE INC.$10,757Research paymentCash or cash equivalentStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Co2025
2025-04-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-03-28Medtronic, Inc.$2,888Research paymentCash or cash equivalentONYX 18 Device, Liquid EmbolicsEMBOLISE2025
2025-03-21Incyte Corporation$7,999Space rental or facility fees (teaching hospital only)Cash or cash equivalentJAKAFI Drug, Hematology/Oncology2025
2025-03-03ABBVIE INC.$3,410Research paymentCash or cash equivalentA Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl2025
2025-03-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-02-27PTC Therapeutics, Inc.$5,464Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2025
2025-02-25ARGENX US, INC.$18,014Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-02-18CSL Behring$8,550Research paymentCash or cash equivalentA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2025
2025-02-18CSL Behring$4,500Research paymentCash or cash equivalentA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2025
2025-02-18CSL Behring$550Research paymentCash or cash equivalentA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2025
2025-02-18CSL Behring$182Research paymentCash or cash equivalentA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2025
2025-02-11CSL Behring$2,700Research paymentCash or cash equivalentA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2025
2025-02-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025
2025-01-09Regeneron Pharmaceuticals, Inc.$14,050Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2025
2025-01-09ABBVIE INC.$129Research paymentCash or cash equivalentM24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmonipl2025
2025-01-07Regeneron Pharmaceuticals, Inc.$4,347Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2025
2025-01-07Regeneron Pharmaceuticals, Inc.$135Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2025
2025-01-01ARGENX US, INC.$70Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.0% in Oct 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.